Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis.
Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination.
Multiple sclerosis immunology: The healthy immune system vs the MS immune system.
Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?
CHMP adopts positive opinion for PLEGRIDY™ (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union
Physicians from Accentia and Johns Hopkins University present plans for new MS drug study for Cyrevia
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis; Acquires Bayer’s Hematologic Oncology Portfolio; First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.
Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
LKB1-regulated adaptive mechanisms are essential for neuronal survival following mitochondrial dysfunction.
Rituximab for refractory digital infarcts and ulcers in systemic sclerosis.
Mitoxantrone-induced suicidal erythrocyte death.
Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis.
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status
Isolation of Clostridium perfringens Type B in an Individual at First Clinical Presentation of Multiple Sclerosis Provides Clues for Environmental Triggers of the Disease.
Fingolimod Impedes Schwann Cell-Mediated Myelination: Implications for the Treatment of Immune Neuropathies?Effect of Fingolimod on Schwann Cells.
Santhera Announces Successful Outcome of Phase III Study with Catena®/Raxone® in Duchenne Muscular Dystrophy
Fourth Cooperative Meeting of Consortium of MS Centers and Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Refining diagnosis of multiple sclerosis with revised MRI criteria.
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.
Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
European Medicines Agency

Pages